Abstract |
The Cell Cycle Profiling - Risk Score (C2P-RS) based on CDK1 and CDK2 specific activities was significantly associated with relapse in breast cancers. We evaluated the prognostic value of the C2P-RS classification using a Japanese cohort including node-negative, hormone receptor-positive breast cancers treated with adjuvant endocrine therapy alone as systemic therapy. Of 266 patients, 22 (8.3%) relapsed within 5 years after surgery. The distribution of each C2P-RS group was 71.8% in the low group, 12.0% in the intermediate group, and 16.2% in the high group. The 5-year relapse-free survival rate in the low C2P-RS group (97.3%) was significantly higher than that in the intermediate C2P-RS group (84.3%) or the high C2P-RS group (74.4%) (P < 0.001). The univariate analysis demonstrated that age, tumor size, histologic grade, and HER2 had no significant correlations with relapse but the C2P-RS classification (P < 0.001) and Ki-67 (P = 0.009) were significantly associated with relapse. Multivariate analysis showed only that the C2P-RS classification was a significant independent prognostic indicator. The C2P-RS classification might be a significant predictor of earlier recurrence in node-negative, hormone receptor-positive breast cancers treated with endocrine therapy.
|
Authors | Seung Jin Kim, Norikazu Masuda, Fumine Tsukamoto, Hideo Inaji, Futoshi Akiyama, Hiroshi Sonoo, Junichi Kurebayashi, Katsuhide Yoshidome, Masahiko Tsujimoto, Hiroyuki Takei, Shinobu Masuda, Seigo Nakamura, Shinzaburo Noguchi |
Journal | Cancer letters
(Cancer Lett)
Vol. 355
Issue 2
Pg. 217-23
(Dec 28 2014)
ISSN: 1872-7980 [Electronic] Ireland |
PMID | 25218592
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Antineoplastic Agents, Hormonal
- Receptors, Estrogen
- Receptors, Progesterone
- Receptor, ErbB-2
- CDC2 Protein Kinase
- CDK1 protein, human
- CDK2 protein, human
- Cyclin-Dependent Kinase 2
- Cyclin-Dependent Kinases
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Breast Neoplasms
(drug therapy, genetics, metabolism, pathology)
- CDC2 Protein Kinase
- Cell Cycle
(genetics, physiology)
- Chemotherapy, Adjuvant
(methods)
- Cyclin-Dependent Kinase 2
(genetics, metabolism)
- Cyclin-Dependent Kinases
(genetics, metabolism)
- Disease-Free Survival
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
(enzymology, genetics, metabolism, pathology)
- Prognosis
- Receptor, ErbB-2
(genetics, metabolism)
- Receptors, Estrogen
(metabolism)
- Receptors, Progesterone
(metabolism)
- Retrospective Studies
- Risk
- Young Adult
|